| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb596f03d029321340c965e75de6564a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-177
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-605
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26 |
| filingDate |
2012-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1fcedc6b1652e979439b1112dda85707
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c9a85ad2fb278d520fd091a92b02893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7689e61dfc2b480f7bd405e964bc446c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_428cb943f1059bf35ef2d30962422ca7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_98d2775343b90b5ed3c3c5e06e1607fc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa6ac2e491fddb305161932d8c0ada75 |
| publicationDate |
2020-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
BR-112013031794-B1 |
| titleOfInvention |
peptides derived from oxintomodulin and their use, polynucleotide, pharmaceutical composition and their use and method for the prevention or treatment of obesity comprising the same |
| abstract |
new oxytomodulin derivatives and pharmaceutical composition for the treatment of obesity comprising them. the present invention relates to a new peptide that exhibits excellent activity at a glucagon-like peptide-1 receptor and a greater glucagon receptor than native oxintomodulin and a composition for the prevention or treatment of obesity comprising the peptide as an active ingredient . unlike native oxintomodulin, the new peptide of the present invention reduces food intake, suppresses gastric emptying and facilitates lipolysis with reduced side effects, also demonstrating excellent receptor activating effects. thus, it can be widely used to treat obesity safely and effectively. |
| priorityDate |
2011-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |